Chiba Cancer Center, Research Institute, 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan; Division of Cancer Immunology, National Cancer Center, Research Institute, Exploratory Oncology Research and Clinical Trial Center (EPOC), 6-5-1 Kashiwanoha, Tokyo 104-0045, Kashiwa 277-8577, Japan; Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka 545-8585, Japan.
Chiba Cancer Center, Research Institute, 666-2 Nitona-cho, Chuo-ku, Chiba 260-8717, Japan; Department of Dermatology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan; Department of Dermatology, University of Yamanashi, Chuo, Japan.
Cell Rep. 2022 Feb 1;38(5):110331. doi: 10.1016/j.celrep.2022.110331.
PD-1 blockade exerts clinical efficacy against various types of cancer by reinvigorating T cells that directly attack tumor cells (tumor-specific T cells) in the tumor microenvironment (TME), and tumor-infiltrating lymphocytes (TILs) also comprise nonspecific bystander T cells. Here, using single-cell sequencing, we show that TILs include skewed T cell clonotypes, which are characterized by exhaustion (T) or nonexhaustion signatures (T). Among skewed clonotypes, those in the T, but not those in the T, cluster respond to autologous tumor cell lines. After PD-1 blockade, non-preexisting tumor-specific clonotypes in the T cluster appear in the TME. Tumor-draining lymph nodes (TDLNs) without metastasis harbor a considerable number of such clonotypes, whereas these clonotypes are rarely detected in peripheral blood. We propose that tumor-infiltrating skewed T cell clonotypes with an exhausted phenotype directly attack tumor cells and that PD-1 blockade can promote infiltration of such T clonotypes, mainly from TDLNs.
PD-1 阻断通过在肿瘤微环境(TME)中重新激活直接攻击肿瘤细胞(肿瘤特异性 T 细胞)的 T 细胞,发挥对各种类型癌症的临床疗效,肿瘤浸润淋巴细胞(TILs)也包括非特异性旁观者 T 细胞。在这里,我们使用单细胞测序表明,TILs 包括偏倚的 T 细胞克隆型,其特征是衰竭(T)或非衰竭特征(T)。在偏倚的克隆型中,T 簇中的那些而不是 T 簇中的那些对自体肿瘤细胞系有反应。在 PD-1 阻断后,T 簇中不存在的非预先存在的肿瘤特异性克隆型出现在 TME 中。没有转移的肿瘤引流淋巴结(TDLNs)中存在大量此类克隆型,而在外周血中很少检测到这些克隆型。我们提出,具有衰竭表型的肿瘤浸润性偏倚 T 细胞克隆型直接攻击肿瘤细胞,并且 PD-1 阻断可以促进此类 T 克隆型的浸润,主要来自 TDLNs。